2025 Q3 -tulosraportti
77 päivää sitten45 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
237 771
Myynti
Määrä
262 964
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 371 | - | - | ||
| 4 248 | - | - | ||
| 234 | - | - | ||
| 429 | - | - | ||
| 227 | - | - |
Ylin
193,8VWAP
Alin
190,25VaihtoMäärä
74,7 388 727
VWAP
Ylin
193,8Alin
190,25VaihtoMäärä
74,7 388 727
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 388 727 | 388 727 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 388 727 | 388 727 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 12.3. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 14.11.2025 | |
| 2025 Q2 -tulosraportti | 26.8.2025 | |
| 2025 Q1 -tulosraportti | 9.5.2025 | |
| 2024 Q4 -tulosraportti | 5.3.2025 | |
| 2024 Q3 -tulosraportti | 15.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenGood that we have a share buyback which supports the share price. Otherwise, it would have looked really bad.·1 päivä sittenDo you think 2.53% is a big short - It's just a poorly managed company with a bad track record. - who would bother to own it
·2 päivää sittenThe stock purchase doesn't really stabilize anything. The short position is stronger. The Bavarian stock should be well over 200.·2 päivää sittenSEB lowers the target price for Bavarian Nordic to 280 Danish kroner (290), reiterates buy Why make such an adjustment? - they then mean that the share is 790 million less worth
·23.1.Close today at 08:17 ∙ MarketWire Premium Bavarian Nordic has entered into an agreement with Eurofarma for the sale and distribution of the company's chikungunya vaccine in Brazil. Eurofarma also obtains a right of first refusal for any future opportunity to register and commercialize the chikungunya vaccine in the rest of Latin America. Bavarian announced this Friday morning. The agreement is based on transfer price and royalties without associated upfront or milestone payments. Eurofarma will be responsible for seeking and maintaining regulatory approval for the vaccine in the exclusive territories, as well as for sales and distribution costs. Bavarian Nordic will continue to be the manufacturer of the vaccine, which will be made available to Eurofarma through a transfer price agreement, it is stated. Chikungunya is a mosquito-borne disease caused by the chikungunya virus, which typically causes acute symptoms, including fever, rash, fatigue, headache, and often severe and debilitating joint pain. Last year, nearly 500,000 cases of chikungunya and over 200 deaths were reported worldwide. And more than half of the reported cases and related deaths originated from Brazil, Bavarian states. Regulatory submission is expected to take place later in the first half of 2026, which could potentially support the launch of the chikungunya vaccine in Brazil in the second half of 2027. "Following a successful launch of our chikungunya vaccine for travelers in the first Western markets in 2025, we are pleased to also expand commercial availability for endemic populations through this first distribution agreement," says Paul Chaplin, CEO of Bavarian Nordic, about the agreement. Although the agreement aims to significantly improve access to chikungunya vaccines in Brazil, it is not expected to have a significant financial impact for Bavarian Nordic in the short to medium term. Eurofarma was founded in 1972 and is a market leader in medical prescriptions in Brazil. The company operates throughout Latin America with retail leadership in the region and also has operations in the USA and Africa with more than 13,500 employees and 11 production facilities. .\˙ MarketWire·23.1.Here we go with bavarian again - a good piece of news and then we're going into the red - crap stock
·20.1.That must surely be "headline news", that Valvena has withdrawn their application for chikungunya vaccine and Bavarian is now the only one on the market...
·22.1.Yes, stop the whining - I also exited on the takeover bid - but again it was also a really good offer. I'm in again on my pension depot but must say that Novo just looks better - however, it's really really good news with valvena and alone about chigunblabla - I'm cautiously optimistic there - and will definitely consider building on here. Agree with topsil - slowly and in the long run. I still think it's a super fine company - in Danish hands and with nice untapped potential - where both mpox and chikunblabla can trigger good increases - but where it's just their ability to develop the travel vaccine business that is the big long-term gain.
20.1.20.1.Good news for Bavarian bad news for Valneva 🛡️ What this means for Valneva’s Portfolio By withdrawing IXCHIQ from the U.S., Valneva is effectively "conceding" the American market to Bavarian Nordic for the foreseeable future.
·20.1.You can see it under news here on the page. One could argue that it should largely have been priced in after Valneva had their marketing authorization withdrawn due to side effects of the vaccine. I.e. BAVA was alone on the market before this and still is after this. However, a small probability that Valneva, through new trials, had proven that their vaccine was less dangerous than assumed and that it would therefore be allowed to re-enter the market, has disappeared.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
77 päivää sitten45 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenGood that we have a share buyback which supports the share price. Otherwise, it would have looked really bad.·1 päivä sittenDo you think 2.53% is a big short - It's just a poorly managed company with a bad track record. - who would bother to own it
- ·2 päivää sittenThe stock purchase doesn't really stabilize anything. The short position is stronger. The Bavarian stock should be well over 200.·2 päivää sittenSEB lowers the target price for Bavarian Nordic to 280 Danish kroner (290), reiterates buy Why make such an adjustment? - they then mean that the share is 790 million less worth
- ·23.1.Close today at 08:17 ∙ MarketWire Premium Bavarian Nordic has entered into an agreement with Eurofarma for the sale and distribution of the company's chikungunya vaccine in Brazil. Eurofarma also obtains a right of first refusal for any future opportunity to register and commercialize the chikungunya vaccine in the rest of Latin America. Bavarian announced this Friday morning. The agreement is based on transfer price and royalties without associated upfront or milestone payments. Eurofarma will be responsible for seeking and maintaining regulatory approval for the vaccine in the exclusive territories, as well as for sales and distribution costs. Bavarian Nordic will continue to be the manufacturer of the vaccine, which will be made available to Eurofarma through a transfer price agreement, it is stated. Chikungunya is a mosquito-borne disease caused by the chikungunya virus, which typically causes acute symptoms, including fever, rash, fatigue, headache, and often severe and debilitating joint pain. Last year, nearly 500,000 cases of chikungunya and over 200 deaths were reported worldwide. And more than half of the reported cases and related deaths originated from Brazil, Bavarian states. Regulatory submission is expected to take place later in the first half of 2026, which could potentially support the launch of the chikungunya vaccine in Brazil in the second half of 2027. "Following a successful launch of our chikungunya vaccine for travelers in the first Western markets in 2025, we are pleased to also expand commercial availability for endemic populations through this first distribution agreement," says Paul Chaplin, CEO of Bavarian Nordic, about the agreement. Although the agreement aims to significantly improve access to chikungunya vaccines in Brazil, it is not expected to have a significant financial impact for Bavarian Nordic in the short to medium term. Eurofarma was founded in 1972 and is a market leader in medical prescriptions in Brazil. The company operates throughout Latin America with retail leadership in the region and also has operations in the USA and Africa with more than 13,500 employees and 11 production facilities. .\˙ MarketWire·23.1.Here we go with bavarian again - a good piece of news and then we're going into the red - crap stock
- ·20.1.That must surely be "headline news", that Valvena has withdrawn their application for chikungunya vaccine and Bavarian is now the only one on the market...·22.1.Yes, stop the whining - I also exited on the takeover bid - but again it was also a really good offer. I'm in again on my pension depot but must say that Novo just looks better - however, it's really really good news with valvena and alone about chigunblabla - I'm cautiously optimistic there - and will definitely consider building on here. Agree with topsil - slowly and in the long run. I still think it's a super fine company - in Danish hands and with nice untapped potential - where both mpox and chikunblabla can trigger good increases - but where it's just their ability to develop the travel vaccine business that is the big long-term gain.
- 20.1.20.1.Good news for Bavarian bad news for Valneva 🛡️ What this means for Valneva’s Portfolio By withdrawing IXCHIQ from the U.S., Valneva is effectively "conceding" the American market to Bavarian Nordic for the foreseeable future.·20.1.You can see it under news here on the page. One could argue that it should largely have been priced in after Valneva had their marketing authorization withdrawn due to side effects of the vaccine. I.e. BAVA was alone on the market before this and still is after this. However, a small probability that Valneva, through new trials, had proven that their vaccine was less dangerous than assumed and that it would therefore be allowed to re-enter the market, has disappeared.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
237 771
Myynti
Määrä
262 964
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 371 | - | - | ||
| 4 248 | - | - | ||
| 234 | - | - | ||
| 429 | - | - | ||
| 227 | - | - |
Ylin
193,8VWAP
Alin
190,25VaihtoMäärä
74,7 388 727
VWAP
Ylin
193,8Alin
190,25VaihtoMäärä
74,7 388 727
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 388 727 | 388 727 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 388 727 | 388 727 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 12.3. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 14.11.2025 | |
| 2025 Q2 -tulosraportti | 26.8.2025 | |
| 2025 Q1 -tulosraportti | 9.5.2025 | |
| 2024 Q4 -tulosraportti | 5.3.2025 | |
| 2024 Q3 -tulosraportti | 15.11.2024 |
2025 Q3 -tulosraportti
77 päivää sitten45 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 12.3. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 14.11.2025 | |
| 2025 Q2 -tulosraportti | 26.8.2025 | |
| 2025 Q1 -tulosraportti | 9.5.2025 | |
| 2024 Q4 -tulosraportti | 5.3.2025 | |
| 2024 Q3 -tulosraportti | 15.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenGood that we have a share buyback which supports the share price. Otherwise, it would have looked really bad.·1 päivä sittenDo you think 2.53% is a big short - It's just a poorly managed company with a bad track record. - who would bother to own it
- ·2 päivää sittenThe stock purchase doesn't really stabilize anything. The short position is stronger. The Bavarian stock should be well over 200.·2 päivää sittenSEB lowers the target price for Bavarian Nordic to 280 Danish kroner (290), reiterates buy Why make such an adjustment? - they then mean that the share is 790 million less worth
- ·23.1.Close today at 08:17 ∙ MarketWire Premium Bavarian Nordic has entered into an agreement with Eurofarma for the sale and distribution of the company's chikungunya vaccine in Brazil. Eurofarma also obtains a right of first refusal for any future opportunity to register and commercialize the chikungunya vaccine in the rest of Latin America. Bavarian announced this Friday morning. The agreement is based on transfer price and royalties without associated upfront or milestone payments. Eurofarma will be responsible for seeking and maintaining regulatory approval for the vaccine in the exclusive territories, as well as for sales and distribution costs. Bavarian Nordic will continue to be the manufacturer of the vaccine, which will be made available to Eurofarma through a transfer price agreement, it is stated. Chikungunya is a mosquito-borne disease caused by the chikungunya virus, which typically causes acute symptoms, including fever, rash, fatigue, headache, and often severe and debilitating joint pain. Last year, nearly 500,000 cases of chikungunya and over 200 deaths were reported worldwide. And more than half of the reported cases and related deaths originated from Brazil, Bavarian states. Regulatory submission is expected to take place later in the first half of 2026, which could potentially support the launch of the chikungunya vaccine in Brazil in the second half of 2027. "Following a successful launch of our chikungunya vaccine for travelers in the first Western markets in 2025, we are pleased to also expand commercial availability for endemic populations through this first distribution agreement," says Paul Chaplin, CEO of Bavarian Nordic, about the agreement. Although the agreement aims to significantly improve access to chikungunya vaccines in Brazil, it is not expected to have a significant financial impact for Bavarian Nordic in the short to medium term. Eurofarma was founded in 1972 and is a market leader in medical prescriptions in Brazil. The company operates throughout Latin America with retail leadership in the region and also has operations in the USA and Africa with more than 13,500 employees and 11 production facilities. .\˙ MarketWire·23.1.Here we go with bavarian again - a good piece of news and then we're going into the red - crap stock
- ·20.1.That must surely be "headline news", that Valvena has withdrawn their application for chikungunya vaccine and Bavarian is now the only one on the market...·22.1.Yes, stop the whining - I also exited on the takeover bid - but again it was also a really good offer. I'm in again on my pension depot but must say that Novo just looks better - however, it's really really good news with valvena and alone about chigunblabla - I'm cautiously optimistic there - and will definitely consider building on here. Agree with topsil - slowly and in the long run. I still think it's a super fine company - in Danish hands and with nice untapped potential - where both mpox and chikunblabla can trigger good increases - but where it's just their ability to develop the travel vaccine business that is the big long-term gain.
- 20.1.20.1.Good news for Bavarian bad news for Valneva 🛡️ What this means for Valneva’s Portfolio By withdrawing IXCHIQ from the U.S., Valneva is effectively "conceding" the American market to Bavarian Nordic for the foreseeable future.·20.1.You can see it under news here on the page. One could argue that it should largely have been priced in after Valneva had their marketing authorization withdrawn due to side effects of the vaccine. I.e. BAVA was alone on the market before this and still is after this. However, a small probability that Valneva, through new trials, had proven that their vaccine was less dangerous than assumed and that it would therefore be allowed to re-enter the market, has disappeared.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
237 771
Myynti
Määrä
262 964
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 371 | - | - | ||
| 4 248 | - | - | ||
| 234 | - | - | ||
| 429 | - | - | ||
| 227 | - | - |
Ylin
193,8VWAP
Alin
190,25VaihtoMäärä
74,7 388 727
VWAP
Ylin
193,8Alin
190,25VaihtoMäärä
74,7 388 727
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 388 727 | 388 727 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 388 727 | 388 727 | 0 | 0 |